Status:
ACTIVE_NOT_RECRUITING
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
Lead Sponsor:
SpyGlass Pharma, Inc.
Conditions:
Cataract
Glaucoma
Eligibility:
All Genders
22+ years
Phase:
PHASE1
PHASE2
Brief Summary
This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild ...
Eligibility Criteria
Inclusion
- Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension
- Planned removal of cataract
- Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception
Exclusion
- Uncontrolled systemic disease
- History of incisional/refractive corneal surgery
- Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliation, or pigmentary glaucoma
- History of incisional glaucoma surgery or intraocular injections
- Other ocular diseases, pathology, or conditions
Key Trial Info
Start Date :
October 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2027
Estimated Enrollment :
201 Patients enrolled
Trial Details
Trial ID
NCT06120842
Start Date
October 13 2023
End Date
November 1 2027
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Advanced Eye Research Institute
Glendale, Arizona, United States, 85306